Franklin, Andrews, Kramer & Edelstein Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Franklin, Andrews, Kramer & Edelstein

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scion who wrote (12542)	2/10/2021 5:59:11 AM
From: scion	of 12881

Common asthma drug cuts COVID-19 hospitalization risk, recovery time - Oxford study By Reuters Staff FEBRUARY 9, 20216:10 PM UPDATED 15 HOURS AGO 2 MIN READ reuters.com (Reuters) - A commonly used asthma treatment appears to reduce the need for hospitalizations as well as recovery time for COVID-19 patients if given within seven days of symptoms appearing, researchers at the University of Oxford said on Tuesday. The findings were made following a mid-stage study of the steroid budesonide, sold as Pulmicort by AstraZeneca Plc and also used for treating smoker’s lung. The 28-day study of 146 patients suggested that inhaled budesonide reduced the risk of urgent care or hospitalization by 90% when compared with usual care, Oxford University said. Researchers said the trial was inspired by the fact that patients with chronic respiratory disease, who are often prescribed inhaled steroids, were significantly under-represented among hospitalized COVID-19 patients during early days of the pandemic. (bit.ly/3q40g1W) Initial data from the study also found volunteers treated with budesonide had a quicker resolution of fever and fewer persistent symptoms. “I am heartened that a relatively safe, widely available and well studied medicine ... could have an impact on the pressures we are experiencing during the pandemic,” said Mona Bafadhel, lead investigator of the trial. Pulmicort was once a blockbuster drug for coronavirus vaccine-maker AstraZeneca, which now offers a newer medicine, Symbicort, as an alternative asthma treatment. Results from the Oxford University study are yet to be published in a peer-reviewed journal. Reporting by Pushkala Aripaka in Bengaluru; Editing by Ramakrishnan M. reuters.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next